Quantcast

Latest Daiichi Sankyo Pharma Development Stories

2011-08-17 08:59:00

PARSIPPANY, N.J., Aug. 17, 2011 /PRNewswire/ -- With the US Food and Drug Administration (FDA) approval today of Zelboraf(TM) (vemurafenib), a first-in-class personalized treatment for patients with unresectable (inoperable) or metastatic melanoma with a BRAF V600E mutation as detected by an FDA-approved test, Daiichi Sankyo prepares to enter the US cancer market with its first oral, targeted anti-cancer therapy. "The Zelboraf approval is not only a significant milestone for these...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related